Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.

Meric‐Bernstam, Funda; N. Saleh, Mansoor; R. Infante, Jeffrey; Goel, Sanjay; S. Falchook, Gerald; I. Shapiro, Geoffrey; Y. Chung, Ki; M. Conry, Robert; S. Hong, David; Sing-Zan Wang, Judy; Steidl, Ulrich; D. Walensky, Loren; Guerlavais, Vincent; Payton, Marie; Allen Annis, D.; Aivado, Manuel; R. Patel, Manish

doi:10.1200/jco.2017.35.15_suppl.2505

Public

Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.

Published in Journal of Clinical Oncology • May 20, 2017

Authors:

Funda Meric‐Bernstam

Mansoor N. Saleh

Jeffrey R. Infante

Abstract

2505 Background: ALRN-6924 is a cell-penetrating stapled alpha-helical peptide designed to equipotently disrupt the interaction between the p53 tumor suppressor protein and its endogenous inhibitors, murine double minute X (MDMX) and 2 (MDM2). For TP53 wild-type (WT) tumors, pharmacological disrupti...

Subject

Medicine

Neutropenia

Anemia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!